A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation

[1]  Tomoyoshi Soga,et al.  Oncometabolites: linking altered metabolism with cancer. , 2013, The Journal of clinical investigation.

[2]  Yiling Lu,et al.  Predicting time to ovarian carcinoma recurrence using protein markers. , 2013, The Journal of clinical investigation.

[3]  Nicholas J. Wang,et al.  Identification and Quantification of AKT Isoforms and Phosphoforms in Breast Cancer Using a Novel Nanofluidic Immunoassay* , 2013, Molecular & Cellular Proteomics.

[4]  J. Hecht,et al.  The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium , 2013, Modern Pathology.

[5]  N. Malats,et al.  ARID1A Alterations Are Associated with FGFR3-Wild Type, Poor-Prognosis, Urothelial Bladder Tumors , 2013, PloS one.

[6]  G. Mills,et al.  Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer , 2012, Genome research.

[7]  Gordon B Mills,et al.  Proteomic classification of breast cancer. , 2012, Current drug targets.

[8]  Thomas Zeng,et al.  Use of mutation profiles to refine the classification of endometrial carcinomas , 2012, The Journal of pathology.

[9]  R. Rustandi,et al.  Applications of imaged capillary isoelectric focussing technique in development of biopharmaceutical glycoprotein‐based products , 2012, Electrophoresis.

[10]  M. Pike,et al.  Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies , 2012, The Lancet. Oncology.

[11]  I. Shih,et al.  TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high‐grade serous carcinoma—evidence supporting the clonal relationship of the two lesions , 2012, The Journal of pathology.

[12]  Jeffrey R. Marks,et al.  Loss of ARID1A-Associated Protein Expression is a Frequent Event in Clear Cell and Endometrioid Ovarian Cancers , 2012, International Journal of Gynecologic Cancer.

[13]  Rosette Lidereau,et al.  PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups , 2012, Breast Cancer Research.

[14]  Tian-Li Wang,et al.  ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. , 2011, Cancer research.

[15]  J. Blaakaer,et al.  The association between endometriosis and gynecological cancers and breast cancer: a review of epidemiological data. , 2011, Gynecologic oncology.

[16]  G. Mills,et al.  High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. , 2011, Cancer discovery.

[17]  H. Mackay,et al.  Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. , 2011, Gynecologic oncology.

[18]  G. Mills,et al.  PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer , 2011, Molecular Cancer Therapeutics.

[19]  H. Kitchener,et al.  First-Line Therapy in Ovarian Cancer Trials , 2011, International Journal of Gynecologic Cancer.

[20]  Richard A. Moore,et al.  ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.

[21]  Tian-Li Wang,et al.  Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.

[22]  G. Mills,et al.  PI3K pathway-directed therapeutic strategies in cancer. , 2010, Current opinion in investigational drugs.

[23]  Fan Zhang,et al.  Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF-β Pathway Signaling Indicates Response to Primary Chemotherapy , 2010, Clinical Cancer Research.

[24]  D. Huntsman,et al.  Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas , 2010, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[25]  A. Reuss,et al.  Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer , 2010, International Journal of Gynecologic Cancer.

[26]  M. Takano,et al.  Randomized Phase II Trial of Paclitaxel Plus Carboplatin Therapy Versus Irinotecan Plus Cisplatin Therapy as First-Line Chemotherapy for Clear Cell Adenocarcinoma of the Ovary: A JGOG Study , 2009, International Journal of Gynecologic Cancer.

[27]  Yiling Lu,et al.  AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. , 2009, Cancer cell.

[28]  V. Velculescu,et al.  Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. , 2009, The American journal of pathology.

[29]  H. Lai,et al.  PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas. , 2009, Gynecologic oncology.

[30]  S. Leung,et al.  Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.

[31]  Zhi Hu,et al.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.

[32]  R. Drapkin,et al.  The distal fallopian tube: a new model for pelvic serous carcinogenesis , 2007, Current opinion in obstetrics & gynecology.

[33]  G. Mills,et al.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.

[34]  P. Vercellini,et al.  Molecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: a critical analysis. , 2006, Human reproduction update.

[35]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[36]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[37]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[39]  K. Ariyoshi,et al.  Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. , 2000, Gynecologic oncology.

[40]  S. Silverberg,et al.  Ovarian tumors associated with atypical endometriosis. , 1988, Human pathology.